Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of compound in reducing protein accumulation for treating Alzheimer's Disease

A technology for senile dementia and compounds, applied in the field of medicine, can solve problems such as no reports on the application, and achieve the effects of improving learning and memory ability, inhibiting the formation of Aβ amyloid deposition, and improving the effect.

Inactive Publication Date: 2018-11-30
NORTHEAST NORMAL UNIVERSITY
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Until March 2018, there were more than 3,400 foreign literature searches on luteolin monomer research reports, most of which focused on the exploration of the role of luteolin on tumor-related signaling pathways, and aimed at antagonizing Aβ protein accumulation. There is no report on its application in the treatment of AD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound in reducing protein accumulation for treating Alzheimer's Disease
  • Application of compound in reducing protein accumulation for treating Alzheimer's Disease
  • Application of compound in reducing protein accumulation for treating Alzheimer's Disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Thioflavin T assay (ThT) for luteolin inhibiting Aβ42 monomer aggregation and MTT assay for inhibiting Aβ42 oligomer-mediated neurotoxic injury

[0029] The protein Aβ protein was synthesized by Nanjing Taopu Biological Co., Ltd., with a purity greater than 95%. The compound luteolin was provided by Shanghai Yuanye Biological Company. The Aβ monomer powder is stored at -80°C. When it is taken out for the first time, it should be allowed to stand at room temperature for 30 minutes, then diluted with hexafluoroisopropanol (HFIP) to 1.0 mg / ml, left to stand for at least 2 hours, and ultrasonicated for 30 minutes to destroy the existing excess Polymer structure, after drying at low temperature, store at -20°C immediately. Thioflavin T (Thioflavin T) was purchased from Sigma (product number T3516-5g). Weigh 0.032g of ThT powder and dissolve it in 20ml of 20mM Tris-HCl (pH 7.4) solution to obtain 5mM ThT mother solution, which is diluted to 5uM when used.

[0030] ...

Embodiment 2

[0034] Example 2 Luteolin and Aβ Protein Transmission Electron Microscopy Experiment (Transmission electron microscopy, TEM)

[0035] The pretreatment was as in Example 1, and then, 5ul of the Aβ protein sample incubated at 37°C for 24 hours was dropped on the surface of a 300-mesh carbon-coated copper grid, air-dried, and negatively stained with 2% (w / v) sodium phosphotungstic acid After 30 seconds, let stand at room temperature for about 4 hours, use JEM-100CXII transmission electron microscope system (JEOL inc., Tokyo, Japan) to detect and take pictures, and the accelerating voltage is 80kV.

[0036] The observation results are attached figure 2 . Compared with the untreated control group, the fiber density, length and width of the Aβ protein in the experimental group (LUT) added to the luteolin compound decreased significantly in a concentration-dependent manner, while the other group of cholinesterase inhibitors Shen (donepezil hydrochloride) has no effect on the inhib...

Embodiment 3

[0037] Example 3 Luteolin and Aβ protein circular dichroism experiment (CD)

[0038] Aβ monomer was mixed with drugs, the final concentration of Aβ was 20uM, and the final concentrations of drugs were 0uM, 10uM, 20uM and 40uM respectively, and after incubation at 37°C for 12 hours with slow shaking, the J-810 spectrometer (Jasco, Japan) was used to detect. The wavelength range is 190-250nm, the resolution is 0.5nm, the spectral width is 2nm, the scanning speed is 100nm / min, the response time is 1s, and the measurement temperature is normal temperature. The solution was added to a quartz cuvette with an optical path of 0.1 mm for measurement, and each experiment was repeated three times. Subtract the buffer curve from the scan curve obtained each time as the experimental result, each experiment was repeated three times, and the average value was given.

[0039] Using the software Jascow32 data analysis provided by the instrument manufacturer to find (attached image 3 ), the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of luteolin in antagonizing the accumulation of beta-amyloid protein, improving cognitive memory and reducing senile plaques. The Alzheimer's disease (AD) is a neurodegenerative disease characterized by neurofibrillary tangles, beta-amyloid (A beta) plaque deposition, and cognitive decline, The accumulation of extracellular toxicity of A beta protein is considered as one of the main links in the pathogenesis of AD. The luteolin can significantly inhibit the accumulation of beta-amyloid protein 1-42 monomers to form fibers, inhibits the formation of a betasecondary structure, and improves the spatial memory learning ability of AD mice and significantly eliminates amyloid plaques in the brain tissue of APP / PS1 double transgenic AD model mice. The luteolin can be applied to the treatment of Alzheimer's disease and related drug development.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to the application of luteolin in the preparation of medicines for treating Alzheimer's disease by antagonizing the accumulation of β-amyloid 1-42 (Aβ42) as a target. Background technique [0002] Alzheimer's disease (AD), also known as Alzheimer's disease, is clinically manifested as psychomotor abnormalities, language disorders, cognitive and memory impairments, and is a common progressive neurological decline in the elderly. According to the World Alzheimer's Report 2009, the number of people living with the disease will soar to 150 million by 2050 [1] . [0003] The most widely accepted theory about the pathogenesis of AD is the Aβ theory marked by the oligomerization of β-amyloid protein and the formation of fibrous precipitates. [2] . Under normal physiological conditions, the generation and degradation of Aβ from the hydrolysis of β-amyloid precursor protein ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P25/28
CPCA61K31/352A61P25/28
Inventor 李晓萌王立春董旭刘欣彤李江
Owner NORTHEAST NORMAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com